LAG3 as a marker of immune activation in esophageal squamous carcinoma treated with concurrent chemoradiotherapy.

ABSTRACT:

Introduction

Esophageal squamous carcinoma (ESCC) is a common malignant tumor of the gastrointestinal tract with high morbidity and mortality rates. Lymphocyte activation gene-3 (LAG3), an important suppressive immune checkpoint in tumor immunity, exhibits a wobbling effect in the prediction of ESCC efficacy.

Methods

Tumor bite paraffin-embedded specimens from 84 patients diagnosed with ESCC, all of whom received radical concurrent chemoradiotherapy (CCRT) at our institution, were screened. For each tissue, we delineated the partitions and analyzed the spatial distribution of the tumor in an in situ immune microenvironment. The density and regional characteristics of immune factor-positive cells, together with the dynamics of various cells based on treatment regimens, were c

SUBMITTER: Zhang Y 

PROVIDER: S-EPMC12103390 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature